Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Change In Receivables?

Shenzhenlubris Pharmaceuticals Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Shenzhenlubris Pharmaceuticals Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Shenzhenlubris Pharmaceuticals Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥4 Mil. It means Shenzhenlubris Pharmaceuticals Co's Accounts Receivable declined by ¥4 Mil from Dec. 2022 to Dec. 2023 .

Shenzhenlubris Pharmaceuticals Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥470 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Shenzhenlubris Pharmaceuticals Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 39.33.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shenzhenlubris Pharmaceuticals Co's liquidation value for the three months ended in Mar. 2024 was ¥828 Mil.

Shenzhenlubris Pharmaceuticals Co Change In Receivables Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Change In Receivables Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

356.35

613.45

69.98

-89.42

3.96

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Shenzhenlubris Pharmaceuticals Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shenzhenlubris Pharmaceuticals Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	470.274	/	1090.969	*	91
=	39.33

2. In Ben Graham's calculation of liquidation value, Shenzhenlubris Pharmaceuticals Co's accounts receivable are only considered to be worth 75% of book value:

Shenzhenlubris Pharmaceuticals Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1594.423	-	1347.802	+	0.75 * 470.274	+	0.5 * 457.277
=	828

Shenzhenlubris Pharmaceuticals Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines